Re: “Protective Role of Silymarin and Deferoxamine against Iron Dextran-Induced Renal Iron Deposition in Male Rats,” and “Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model”

International Journal of Preventive Medicine, Vol 5, No 6, June, 2014 800 DEAR EDITOR, Recently, two articles entitled “Protective role of silymarin (SM) and deferoxamine (DF) against iron dextran‐induced renal iron deposition in male rats,” and “Co‐administration of SM and DF against kidney, liver, and heart iron deposition in male iron overload rat model” were published in International Journal of Preventive Medicine. The authors used two different models of iron overloading in rats and investigated the protective role of SM, DF and combination of both against iron dextran‐induced renal iron deposition. However, they did not report the change of liver enzymes. There are some mechanisms that shows iron overload make liver injuries such as, hepatocellular necrosis, inflammation, and in some cases even carcinoma. Therefore, we measured and analyzed the serum level of alanine aminotransferase (ALT), aspartate amino transferase (AST) and alkaline phosphatase (ALP) in animals of these two protocols of iron overloading (see published Re: “Protective Role of Silymarin and Deferoxamine against Iron Dextran‐Induced Renal Iron Deposition in Male Rats,” and “Co‐Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model”